- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Opioid-induced constipation treatment market to rise to $652.4 million by 2019
1 December 2015 • Author: Victoria White
The opioid-induced constipation treatment market across the six major countries of the US, Germany, France, Italy, Spain and the UK will increase from an estimated $66.7 million in 2014 to $652.4 million by 2019, according to research and consulting firm GlobalData.
The company’s latest report, OpportunityAnalyzer: Opioid-Induced Constipation – Opportunity Analysis and Forecasts to 2019, states that the rising number of opioid-induced constipation sufferers is largely down to overall population increase and the continued use of opioids in the treatment of chronic non-cancer pain, which is driving impressive market growth.
Claire Gibson, Ph.D., GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, says that the introduction of novel targeted oral therapies for opioid-induced constipation, such as peripherally-acting mu-opioid receptor antagonists (PAMORAs), will be a major driver of market growth during the forecast period.
Gibson explains: “While there is currently only one approved PAMORA, AstraZeneca’s Movantik, the anticipated approval of another four PAMORAs in the US and Europe during the forecast period will mark a shift in the way that drugs for opioid-induced constipation are prescribed.
“Although laxatives are likely to remain the first-line therapy, the advent of these highly-targeted drugs will increase the number of patients receiving non-laxative prescription treatments for opioid-induced constipation.”
US sales will represent 86% of the total market in 2019
GlobalData’s report also states that the majority of sales will come from the US, which will represent approximately 86% of the total market in 2019.
Gibson continues: “The US is responsible for consuming 80% of the global opioid supply, despite making up just 4.6% of the global population. Opioids are the most commonly prescribed class of medication in the US, which is mainly due to an increasing awareness of chronic pain and its effect on patient quality of life.
“Patient and physician awareness is key to the development and use of opioid-induced constipation treatment, with US sales figures demonstrating the impact such awareness can have on the market.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics